聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2026

HIGHLIGHTS FOR THE PERIOD ENDED 30 JUNE 2026

- For the period ended 30 June 2026 (the "**Period**"), the Group's revenue reached approximately HK$273.8 million, with net profit standing at approximately HK$31.2 million. Cash generation remained solid, with operating cash flow at approximately HK$11.4 million.
- Despite temporary earnings compression resulting from regulatory adjustments and front-loaded investments in R&D, commercialization, and international expansion, the Group demonstrated operational resilience by remaining profitable and financially strong.
- As at 30 June 2026, total equity increased by 8.6% to approximately HK$448.7 million, reflecting a strengthened capital base. The debt-to-equity ratio improved to 34.9%, demonstrating active deleveraging and prudent capital stewardship.

- Revenue of Bogutai® increased significantly from approximately HK$65.6 million to approximately HK$91.4 million, representing an increase of 39.3% year-on-year ("**YoY**"). The strong growth was primarily attributed to the ongoing market development and engagement with this innovative osteoporosis therapy within the medical community and among patients in China. As of the first quarter of 2026, Bogutai® ranked second in overall market share and first in the retail channel among teriparatide products in China. Its nationwide sales surpassing those of the originator brand, achieving these market positions within approximately two years of commercial launch. The Group is in active preparation the drug's U.S. FDA submission, expecting FDA approval anticipated to be received in 2027. Bogutai® is expected to become the Group's first product to achieve overseas commercialization, marking a significant milestone in its global expansion strategy.
- The Group is advancing the development of its BMP-2 regenerative medicine program. Utilizing its proprietary ECO-KSFA® platform, the Group has successfully established a high-yield production process for BMP-2 API, a crucial growth factor in regenerative medicine widely applied in spinal fusion and bone defect reconstruction. During the Period, the Group completed pilot-scale manufacturing process for the BMP-2 drug substance and initiated development of a sustained-release gel formulation, laying a solid foundation for finalizing the product's clinical dosage form.
- The next-generation generic antifungal drug, Isavuconazonium sulfate capsules, completed all supplementary studies required by the regulator and the Group is preparing to submit the corresponding documentation to the Center for Drug Evaluation (CDE) in the second half of 2026. To support future commercialization, the Group has commissioned a dedicated production line specifically designed for the product and established strategic partnerships with high-quality API suppliers to ensure reliable manufacturing capacity and supply for commercialization.

* *For identification purposes only*

The board (the "**Board**") of directors (the "**Directors**") of the Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**" or "**Uni-Bio**") is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2026 (the "**1H2026**" or the "**Period**") as follows:

KEY FINANCIAL HIGHLIGHTS

For the six months ended 30 June (Unaudited)

	2026	2025
Revenue *(HK$'000)*	**273,783**	310,225
Gross profit *(HK$'000)*	**222,705**	254,084
R&D expenses (including capitalised portion) *(HK$'000)*	**21,450**	13,634
Profit before taxation	**37,327**	78,649
EBITDA *(HK$'000)*	**53,531**	92,120
Gross profit margin *(%)*	**81.3%**	81.9%
R&D costs (including capitalised portion) to revenue *(%)*	**7.8%**	4.4%
As at 30 June/31 December		
Cash ratio *(times) (note: bank balance and cash/ current liability)*	**1.33**	1.63
Current ratio *(times) (note: current asset/ current liability)*	**2.93**	3.23
Trade payable turnover days *(days)*	**71**	67
Trade receivables turnover days *(days)*	**62**	43
Inventory turnover days *(days)*	**147**	131
Debt-to-equity ratio *(%) (note: liability/shareholders' equity)*	**34.9%**	40.3%
Total assets turnover *(%) (note: current revenue/total assets)*	**90.4%**	101.1%

UNAUDITED FINANCIAL FIGURES BASED ON REPORTABLE SEGMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND 2025

	Period ended 30 June		
	2026	2025	
	HK$'000	*HK$'000*	**Change**
Revenue from sales of marketed biological and chemical pharmaceutical products	**273,783**	310,225	-11.7%
Cost of sales	**(51,078)**	(56,141)	-9%
Gross profit	**222,705**	254,084	-12.4%
Other net losses	**1,352**	(3,599)	-137.6%
Selling and distribution expenses	**(136,222)**	(131,679)	3.4%
General and administrative and other expenses	**(33,224)**	(30,191)	10.0%
Equity-settled share-based payment expenses	**(376)**	–	N/A
Operating profit from marketed biological and chemical pharmaceutical products	**54,235**	88,615	-38.8%
Other revenue	**3,494**	4,426	-21.0%
Research and development costs	**(19,528)**	(13,634)	43.2%
Finance costs	**(874)**	(758)	15.2%
Profit before taxation	**37,327**	78,649	-52.5%

MARKET REVIEW

China's pharmaceutical industry achieved a strategic elevation in 2026, with the Government Work Report formally designating it as an "emerging pillar industry" for the first time. Driven by this policy tailwind, the sector maintained strong momentum in innovation-led growth. During the first half of 2026, 38 innovative drugs received marketing approval, including 11 domestically developed therapies, surpassing the full-year approval total for 2025. Concurrently, China's innovative medicines expanded their global presence, with cross-border out-licensing transaction volume approaching US$110 billion in the first half of 2026. This total represents nearly 80% of the full-year figure recorded in 2025 and more than double the level in 2024, reflecting surging global confidence in China's biopharmaceutical R&D capabilities, manufacturing standards, and clinical pipelines.

The domestic pharmaceutical landscape experienced ongoing structural changes in policy during the first half of 2026. Effective 1 January 2026, the transition of general biological products from the 3% simplified value-added tax (VAT) regime to the 13% general taxation regime increased effective tax burdens across the sector, driving end-market price adjustments. Centralized volume-based procurement (VBP) rules were further optimized to promote rational pricing, prioritize supply stability, and curb unsustainable low bidding. However, persistent VBP price compression within in-hospital channels accelerated the industry's shift toward out-of-hospital commercialization. Subsequently, the out-of-hospital segment has emerged as a crucial growth driver. According to Frost & Sullivan, China's out-of-hospital pharmaceutical market is projected to reach RMB1,815.5 billion by 2035, representing a compound annual growth rate (CAGR) of 9.3% from 2024.

The medical aesthetics sector maintained robust expansion, supported by growing consumer demand for non-invasive procedures and ongoing product innovation. The global medical aesthetics market is estimated to reach US$159.4 billion in 2026 and expand to US$401.3 billion by 2035 at a CAGR of 10.8%. During the first half of 2026, the industry in China entered a new phase of comprehensive, end-to-end regulatory oversight. This strengthened regulatory and policy architecture is expected to foster a healthier, more transparent market landscape, creating a favorable operating environment for compliant industry leaders backed by strong R&D pipelines and differentiated product portfolios.

BUSINESS REVIEW

Uni-Bio Science Group — A Fully Integrated Biopharmaceutical Company and A Future Global Leader in Regenerative Medicine

Uni-Bio Science Group is an innovative biopharmaceutical company committed to powering the advancement of regenerative medicine with next- generation synthetic biology and complex peptide innovation. Focusing on four core research areas, including muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT (Ear, Nose, and Throat) regeneration, the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP- compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.

As of 30 June 2026, the Group has eight products in the market, namely GeneTime®, GeneSoft®, Pinup®, Boshutai®, Bogutai®, 肌顏態®, 金因康® and 金因敷®.

KEY HIGHLIGHTS IN THE FIRST HALF OF 2026

Strong Financial Resilience Supports Strategic Transition and Sustains Long-Term Growth

Toward the end of 2025, the Group elevated its long-term corporate strategy from "Stable Growth" to "Innovation-Driven", transitioning from an integrated pharmaceutical firm into a global pioneer in regenerative medicine. During this pivotal transformation, the Group prioritized investments in high-barrier, long-lifecycle biologics, while continuing to advance its regenerative medicine pipeline, commercial execution, and international market penetration, powered by its next-generation synthetic biology and complex peptide/mini-protein platforms. These strategic investments establish a solid foundation for the Group's next stage of sustainable and innovation-led growth, with commercial and financial contributions expected to materialize progressively over time.

Despite temporary earnings compression resulting from regulatory adjustments and front-loaded investments in R&D, commercialization, and international expansion, the Group demonstrated operational resilience by remaining profitable while advancing its strategic transition during the six months ended 30 June 2026 (the "**Period**"). Revenue reached approximately HK$273.8 million, with net profit standing at approximately HK$31.2 million. While these transitional outlays weighed on near-term earnings, management considers them essential to strengthen long-term growth prospects and solidify the Group's positioning as a clinical-value-oriented leader in regenerative medicine.

The Group maintained profitability and remained in a strong financial position to navigate near-term market fluctuations. As at 30 June 2026, total equity increased by 8.6% to approximately HK$448.7 million from that of as at 31 December 2025, reflecting a strengthened capital base. The debt-to-equity ratio improved from 40.3% as at the end of 2025 to 34.9% as at 30 June 2026, demonstrating active deleveraging and prudent capital stewardship. Cash generation remained solid during the Period, with operating cash flow at approximately HK$11.4 million. This cash level provides ample liquidity and financial flexibility to support ongoing R&D, commercial rollout, and global expansion.

Bogutai® Maintains Strong Commercial Momentum While Accelerating Global Expansion

Since its commercial launch in 2024, the Group's flagship product, Bogutai®, has established a strong brand position in innovative osteoporosis management. It serves as a commercial benchmark for the Group, demonstrating the successful execution of an omnichannel distribution network across China driven by targeted academic promotion and patient education.

During the Period, the Group hosted over 1,000 academic symposiums engaging over 20,000 healthcare professionals nationwide, reinforcing physician awareness of Bogutai®'s differentiated clinical benefits. Additionally, the Group conducted over 60 dedicated training sessions for more than 1,200 pharmacy professionals across its retail network. Clinically, Bogutai® gained strong traction, enrolling over 10,000 new patients alongside nearly 10,000 returning patients, reflecting expanding market adoption and high treatment adherence. Supported by a nationwide network spanning tier-1 to tier-4 cities, Bogutai® achieved revenue growth of 39.3% YoY for the Period, driven by strong sales volume expansion that unlocked operating leverage and enhanced profitability.

Building on its domestic success, the Group is accelerating Bogutai®'s global footprint. In addition to its strategic partnership with Kexing Biopharm (Stock Code: 688136.SH) targeting six key international markets, namely Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico, the Group is actively advancing its U.S. Food and Drug Administration (U.S. FDA) regulatory submissions, targeting approval in 2027. Concurrently, management is in active discussions with regional distributors across ten additional overseas markets to tailor localized commercial strategies. Looking ahead, the Group will continue to reinforce Bogutai®'s leadership through compliant academic promotion and patient support, while expanding its global commercial footprint to unlock long-term growth potential.

R&D and Pipeline Progress

Since late 2025, the Group has strategically upgraded its R&D positioning, clearly identifying synthetic biotechnology as the driving force for developing innovative and proprietary products in regenerative medicine. The focus is on key therapeutic areas such as muscular-skeletal regeneration (e.g., PTH-mediated bone formation, BMP-2-induced osteogenesis), skin regeneration (e.g., growth factor-activated tissue repair), ocular regeneration (e.g., Epidermal Growth Factor (EGF)-promoted corneal repair), and ENT regeneration. These areas address core unmet clinical needs and promote the transition of regenerative medicine from the laboratory to broad clinical application through the deep integration of cutting-edge technologies.

Currently, the Group has several leading patented biopharmaceutical products, skincare raw material products and high-value generic drugs under various stages of development. The Group's R&D team is working diligently to research and discover new patented drugs to fulfill the medical needs of patients.

Patented Biopharmaceutical Products

Products/Components	Indication	Discovery	Pre-clinical	Phase 1	Phase 2	Phase 3	BE	NDA	Marketed
Muscular-Skeletal Regeneration									
Bogutai® (Overseas)	Osteoporosis	N/A	✔	CTE	CTE	CTE			
UB107 (BMP-2 Biomedical material)	Bone Repair	✔	✔						
UB106 (Long-acting)	Obesity	✔							
Ocular Regeneration									
EGF (Single-dose eye drops)	Cornea Repair	✔	✔	CTE	CTE	CTE	CTE		
UB102	AMD	✔							
Skin Regeneration									
EGF/bFGF (Hydrogel)	Wound Healing	✔	✔						

Note: BE, bioequivalence, CTE, the abbreviated form of clinical trial exemption, refers to the authorization to administer an investigational agent to patients or volunteer subjects under specified conditions of a particular research study in a clinical setting. Upon approval, the new drug can be exempted from Phase I/II/III clinical trial.

Muscular-Skeletal Regeneration

BOGUTAI® (Overseas) — International Market Expansion

Teriparatide (recombinant human parathyroid hormone) represents a unique hormone-based approach to bone regeneration, a proprietary product that is under R&D of the Group, is effective in treating osteoporosis and bone pain, increasing bone density and reducing the risk of bone fracture. Currently, the drug is the only class of anabolic agent which can actively increase bone density and reduce the chance of vertebral and hip fractures by stimulating osteoblasts activity. Through stimulating new bone formation, Teriparatide can quickly improve bone quality and increase bone density within 6 months of treatment, therefore reducing fracture incidence and bone pain, which is especially helpful in treating patients with moderate-to-severe osteoporosis and ostealgia.

Bogutai® is the first domestic disposable liquid injection pen launched in China in 2024, with unparalleled dosing accuracy and minimized injection pain. It has been proven that it is effective to increase bone density, reduce fracture incidence and it is more convenient and safer for patients to use. Following its successful launch in China, the Group accelerated Bogutai®'s international commercialization strategy by granting exclusive commercialization rights in six key overseas markets, Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico, to Kexing Biopharm in 2025. Through this partnership, Bogutai® will complement Kexing Biopharm's previously licensed Denosumab injection, creating a comprehensive osteoporosis portfolio that combines anti-resorptive and bone-forming therapies, further strengthening the partners' competitive position in the global osteoporosis market. Meanwhile, the Group is actively preparing for the U.S. FDA submission of Bogutai®. The product is expected to benefit from an accelerated regulatory review process, with FDA approval anticipated to be received and launch in the U.S. in 2027. Bogutai® is expected to become the Group's first product to achieve overseas commercialization, marking a significant milestone in its global expansion strategy. The Group has suspended the PTH micro-needle project in order to concentrate its resources on promoting the overseas business of Bogutai®.

EGF (Single-Dose Eye Drops) — Innovative Specification Expansion

The Group's ophthalmic product GeneSoft® is a prescription biologic for corneal repair, widely used in postoperative corneal wound healing and dry eye syndrome treatment in China. In July 2025, the Group obtained China National Medical Products Administration (NMPA) approval for active pharmaceutical ingredient (API) production capacity expansion, enabling future development of additional EGF-based products with new packaging specifications, expanded clinical indications.

Leveraging the newly commissioned Blow-Fill-Seal (BFS) production line in Dongguan, the Group is accelerating development of next-generation GeneSoft® products, including 0.5mL BFS single-dose (daily disposable) format and 3mL BFS multi-dose preservative-free format. The 0.5mL single-dose EGF ophthalmic formulation, indicated for the treatment of corneal epithelial defects, is expected to be commercially launched by the end of 2027, further strengthening the Group's ophthalmology portfolio and expanding its presence in the ocular therapeutics market. Currently, the Group is preparing supplemental marketing approval applications for both formulations, which are expected to be submitted to the NMPA in 2026.

The advanced BFS technology integrates container forming, filling, and sealing in one sterile process. Compared to conventional eye drops, it offers preservative-free formulation, superior container integrity, and lower contamination risk. These advancements provide enhanced medication safety for patients. The technology also improves manufacturing efficiency and cost competitiveness.

UB107 — Bone Repair Biomedical Material

BMP-2, is a pivotal growth factor in regenerative medicine, and UB107 is the Group's BMP-2-based biomedical material candidate recognized for its capacity to recruit and induce differentiation of mesenchymal stem cells (MSCs) into osteogenic lineages. Clinically, it has been extensively utilized in bone defect reconstruction and spinal fusion procedures. The Group successfully developed a BMP-2 API manufacturing process utilizing its proprietary ECO-KSFA® technology platform. Ectopic bone formation can cause pain, limit joint mobility, and lead to functional impairment. It is most commonly seen following orthopedic procedures, during post-injury tissue repair, or in patients with long-term implants. To overcome clinical limitations including burst release and graft migration, while also addressing the risk of ectopic bone formation, the Group is developing an innovative sustained-release hydrogel formulation.

As the Group's first Class III medical device candidate, this product targets multiple orthopedic applications, such as critical-sized bone defects, fracture non-unions, and interbody spinal fusion. The Group expects to complete clinical registration and initiate clinical trials by 2027, with a targeted market launch in 2029.

The Group is actively exploring regenerative therapy combining BMP-2 with stem cell technology for innovative osteoarthritis treatment. MSCs are a cornerstone of regenerative medicine, demonstrating notable efficacy in conditions like diabetic foot and knee osteoarthritis. BMP-2 enhances this process by inducing MSCs to differentiate into chondrocytes, increasing cartilage-specific matrix synthesis vital for cartilage tissue engineering. The Group is collaborating with industry partners to develop BMP-2 and stem cell therapies specifically for knee osteoarthritis.

During the Period, the Group successfully completed the development for API scale manufacturing process for future commercialization. Meanwhile, the Group began development of a sustained-release hydrogel formulation laying the foundation for the product's final dosage form.

UB106 — New Dual-Target Antibody for Obesity

In May 2024, the Group proudly announced a project cooperation agreement with Great Bay Bio (GBB) and TigerMed Pebble Accelerator, a subsidiary of Tigermed. This agreement focuses on the joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, the Group seeks to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical development, and ultimately, commercialization. AI technology has been utilized for molecular screening and affinity maturation, accelerating the R&D the endocrine field but also promises to deliver significant benefits to the vast population of overweight and obese patients.

In 2025, the Group co-developed with GBB a potentially first-in-class dual-target antibody for obesity, designed to promote fat loss while preserving muscle mass. During the Period, the Group obtained encouraging preclinical proof-of-mechanism data from a next-generation body-composition program. In a DIO mouse study, the lead candidate outperformed a clinical-stage benchmark combination in overall weight reduction, fat loss and body-composition improvement, while also mitigating lean-mass loss associated with standard weight-loss therapy, supporting its potential to deliver higher-quality weight loss.

UB102 — DOTBODY™ Molecule in wAMD

UB102 is a novel bispecific nanobody designed to simultaneously target VEGF-A and Ang-2 for the treatment of ocular diseases such as wet age-related macular degeneration (wAMD). Encouraging in vitro data have been generated for the program, demonstrating substantially higher target-binding affinity and cellular blockade activity against both VEGF-A and Ang-2 compared with faricimab, supporting its potential for a best-in-class profile in dual-pathway inhibition.

Building on UB102, a potent anti-inflammatory module targeting a key cytokine pathway has also been developed, providing the potential to integrate angiogenesis and inflammation control within a novel tri-specific therapeutic approach. Together, these findings provide a foundation for the development of a potentially best-in-class tri-specific format and support the exploration of partnership and co-development opportunities with leading global pharmaceutical and biotechnology companies.

According to the Frost & Sullivan Report, the prevalence of wet AMD in China was 3.4 million in 2017 and is expected to reach 4.8 million in 2030. The Group believes that there is a significant commercial demand for the treatment of wet AMD.

Advanced Skincare Raw Materials

Functional skincare continues to gain market traction, while synthetic biology remains an important area of innovation in the cosmetics and medical aesthetics sectors. Leveraging the R&D ecosystem at Hong Kong Science Park, the Group's proprietary bioprocessing platform, and the extensive industry expertise of its partner, Global Cosmetics, the Group has successfully accelerated its commercialization pipeline, most recently launching Type XVII collagen products in late 2025 following the market debut of its fibronectin series in 2023.

To optimize resource allocation toward high-potential assets, the Group has strategically prioritized the commercial scale-up of these lead products while temporarily pausing the development of other medical aesthetics ingredients.

Collagen

Collagen is the most abundant protein in the human body, making up from 25% to 35% of the whole-body protein content. It forms a network of elastic fibers that support the skin, maintaining its elasticity and locking in moisture. Collagen production decreases by approximately 1% each year of age after maturity (about age 21), leading to a loss in firmness and elasticity of the skin. Collagen skincare products could be widely used in moisturizing, maintaining the skin barrier, and anti-aging.

During the Period, the Group secured a landmark patent from the National Intellectual Property Administration (CNIPA) for its proprietary Type XVII collagen ingredient, fortifying its intellectual property portfolio and building a robust defensive barrier alongside its existing Type XVII technologies. Representing a pivotal milestone for the Group's medical aesthetics and premium ingredients business, this patent anchors a clinical-grade raw material supply chain while unlocking multi-scenario downstream applications across medical aesthetic products, functional skincare, and biomedical dressings. In late 2025, the Group launched GeneQueens®, a medical-grade skincare series, further enriching its portfolio in functional skincare and post-procedure medical aesthetics. GeneQueens® features a breakthrough triple-protein formulation integrating Fibronectin, Type III Collagen, and Type XVII Collagen, each precisely calibrated at an industry-leading concentration of 1,000 ppm to deliver synergistic deep repair and advanced anti-aging benefits.

Fibronectin

Fibronectin, a vital extracellular matrix glycoprotein, plays a fundamental role in supporting cell migration, adhesion, proliferation and tissue regeneration. Leveraging its proprietary Skbrella™ FN (Recombinant Human Fibronectin) technology, which integrates AlfaBODY AI® design, HD 3.0 high-density fermentation and pharmaceutical-grade protein ultra-purification, the Group enables the development and production of highly active and high-purity recombinant human fibronectin. The Group has been granted a Chinese invention patent for this technology.

The Group continues to deepen the scientific validation of fibronectin across skin repair and post-procedure care applications. During the Period, the Group's joint research project with the Cosmetics Testing Center of the Hospital for Skin Diseases, Southern Medical University on the wound-healing properties of fibronectin was selected for e-Poster presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This milestone further elevates the international academic recognition and clinical credibility of the Group's proprietary fibronectin technology.

On the commercialization front, the Group continues to expand its fibronectin-based product portfolio across different application scenarios. Building on its existing 肌顏態® Fibronectin Essence and Fibronectin Repair Solution, the Group further launched the 肌顏態® Invigorate Series, which has commenced sales through e-commerce platforms. In addition, the 肌顏態® Fibronectin Repair Liquid received industry acclaim as a "CCEF 2025 Cosmetics Industry Innovative Product". The Group continues to develop differentiated fibronectin formulations to broaden its market presence across functional skincare, medical aesthetic post-procedure care, and adjacent dermatological segments.

High Value Generic Products and Bioequivalence Studies

Product	Indication	Status	Remark
Anti-infection			
Isavuconazonium sulfate capsule	Fungal infection	Marketing application accepted by NMPA	Expected to be approved for launch in the first quarter of 2027

Isavuconazonium Sulfate Capsules Project

Isavuconazonium sulfate capsules, a novel triazole antifungal, are currently the only drug indicated for both Invasive Aspergillosis (IA) and Invasive Mucormycosis (IM). Statistical data shows that sales of Isavuconazonium sulfate in China were minimal at RMB2 million in 2022, and surged to RMB136 million in 2023. In 2024, following its inclusion in the list of medicines covered by the national medical insurance coverage, annual sales of Isavuconazonium sulfate capsules increased to RMB225 million.

The Group is committed to advancing the development and accessibility of Isavuconazonium sulfate capsules, aiming to provide more effective antifungal treatment options and improve the quality of life for patients worldwide. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. During the Period, the Group completed all supplementary studies required by the regulator and is scheduled to submit the corresponding documentation to the Center for Drug Evaluation (CDE) in the second half of 2026. To support future commercialization, the Group has commissioned a dedicated production line specifically designed for the product and established strategic partnerships with high-quality API suppliers to ensure reliable manufacturing capacity and supply. Isavuconazonium sulfate capsules are expected to receive marketing approval in the first quarter of 2027, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections.

Two Proprietary Technology Platforms Driving Regenerative Medicine Innovation

Advanced Synthetic Biology Platform

The Group's ECO-KSFA® synthetic biology platform integrates biosynthesis, AI-assisted protein design, and protein engineering to support the development and large-scale production of peptide and protein therapeutics. Using an E. coli-based system, the platform enhances fermentation efficiency by extending cell lifespan, enabling kilogram-scale peptide production while reducing raw material costs. It is also capable of producing structurally complex, cysteine-rich mini-proteins through gene editing and high-density fermentation. To date, trial production has been completed for two peptide products, and one complex peptide has been successfully developed. The platform will continue to be optimized, with additional candidates under evaluation for clinical potential.

Biological Hydrogel Technology Platform

The Group has established a biological hydrogel technology platform based on thermo-sensitive in-situ gel technology, building on its existing EGF products. This platform currently supports sustained drug release and functions as a cell scaffold, with exploratory research extending into 3D cell culture and bone repair. In parallel, the Group is developing wound repair hydrogel products, including sprayable formulations that rapidly form protective films. Looking ahead, hydrogel research is expected to expand into ocular and aural drug delivery applications, further broadening the platform's therapeutic potential.

RESULTS OVERVIEW

The first half of 2026 marked a strategic transition period for the Group, characterized by portfolio optimization alongside expanding channel and market access. Revenue during the Period was temporarily impacted by strategic VBP pricing adjustments for Pinup® and, to a lesser extent, GeneTime®, coupled with the structural impact of latest biologics VAT policies on net selling price. Gross margin remained relatively resilient. This resilience was underpinned by improved operating leverage for Bogutai®, an increasing revenue contribution from higher-margin biopharmaceuticals, and ongoing cost control initiatives. During the Period, the Group continued to deploy targeted capital into commercial capabilities, pipeline R&D, and international market penetration. It was a deliberate strategy that absorbed near-term profitability to fortify long-term scale. Concurrently, positive momentum in volume expansion, channel penetration, and pipeline milestones has significantly reinforced the Group's foundation for sustainable growth.

For the Period, the Group recorded revenue of approximately HK$273.8 million, representing a decrease of 11.7% YoY. Sales volumes of key products continued to grow during the Period, particularly Bogutai® and GeneTime®. However, revenue was impacted by one-off pricing adjustments implemented during the Period, primarily the repricing of Pinup® upon its successful VBP renewal, the strategic expansion of GeneTime®'s hospital access and prescription base through participation in the Guangdong Alliance Centralized Drug Procurement program, and the net selling price impact arising from the increase in the VAT rate applicable for biological products from 3% to 13%.

Gross profit was approximately HK$222.7 million, representing a decrease of 12.4% as compared with approximately HK$254.1 million for the first half of 2025, whereas as gross profit margin remained stable at 81.3%. General and administrative expenses accounted for 12.1% of revenue for the Period as compared with 9.7% for the same period last year, and selling and distribution expenses for the Period increased to 49.8% of revenue from 42.4% of the corresponding period last year, primarily reflecting continued commercial investment as the Group's product mix shifted further toward biologic products that remain in the volume ramp-up phase, including ongoing marketing initiatives for Bogutai® and efforts to support broader market access and volume growth for GeneTime®. R&D expenses increased by 43.2% YoY to approximately HK$19.5 million, reflecting the continued advancement of the Group's pipeline projects and increased investment in product development.

Profit for the Period decreased by 59.0% YoY to approximately HK$31.2 million. The decrease primarily reflected short-term profitability pressure during the Group's strategic transformation, including lower absolute gross profit resulting from pricing adjustments for certain core products and the VAT-related pricing impact, together with continued investment in commercialization, new product launches, pipeline development, and international expansion. The earnings per share were approximately HK$0.52 cents, compared with HK$1.27 cents in the first half of 2025.

Marketed drugs sales

For the Period, the Group had eight marketed products, namely GeneTime®, GeneSoft®, Pinup®, Boshutai®, Bogutai®, 肌顏態®, 金因康® and 金因敷®, which contributed 34.51%, 6.87%, 21.03%, 3.36%, 33.39%, 0.80%, 0.031% and 0.009% of total revenue of the Group, respectively.

GeneTime®

The Group's flagship product, GeneTime®, is a prescription biological drug for wound healing. During the Period, GeneTime® recorded a decrease of 12.3% in revenue from approximately HK$107.8 million to approximately HK$94.5 million. The decrease was primarily attributable to the strategic price adjustment following its participation in the Guangdong Alliance Centralized Drug Procurement program to broaden hospital access and expand its prescription base, together with the VAT-related pricing impact. Sales volume achieved high-single-digit YoY growth, reflecting continued strong underlying demand and the initial benefits of broader hospital access and prescription-base expansion. The revenue decline mainly reflected the immediate pricing impact, while volume growth following broader hospital and channel access is expected to ramp up progressively.

Beyond the VBP, the Group continued to strengthen the commercialization of GeneTime® through its expanding retail strategy. GeneTime® is now marketed through a diversified distribution network comprising major online platforms, distributors, leading chain pharmacies, and public hospitals, providing patients with more convenient and reliable access to treatment. As of 30 June 2026, the Group established partnerships with nearly 40 of China's top 100 pharmacy chains, covering more than 12,000 retail outlets, with the total number of pharmacies developed approaching 15,000.

GeneSoft®

GeneSoft® is a therapeutic drug for dry eye syndrome, corneal damage and post-operative healing. During the Period, GeneSoft® recorded a 1.6% YoY increase in revenue from approximately HK$18.5 million to approximately HK$18.8 million. The Group is actively expanding GeneSoft®'s presence across major pharmacy chains to diversify sales channels, improve accessibility, and strengthen market reach. In addition, the Group is developing several new specifications in BFS packaging that will enhance product quality and user convenience. Tailored product specifications, packaging variants, and targeted pricing strategies will be deployed across distinct market segments to safeguard profitability.

Pinup®

The Group's self-developed chemical pharmaceutical product Pinup® (Voriconazole tablets) recorded a decrease of 47.1% in revenue from approximately HK$108.9 million to approximately HK$57.6 million for the Period. The revenue contraction primarily reflected the repricing of Pinup® following its successful VBP renewal, which supported continued market access and sales volume growth under the VBP program. The Group has been optimizing its channel mix toward less price-sensitive regions and expanding its presence in retail pharmacy networks outside traditional hospital channels. Furthermore, the Group is strategically positioning its pipeline for recovery. The upcoming launch of a next-generation generic antifungal product, Isavuconazonium sulfate capsules, targeted for early 2027, is expected to broaden the Group's antifungal portfolio and materially mitigate the revenue impact.

Boshutai®

The Group's product Boshutai® (Acarbose tablet) is a small molecule drug to treat diabetes. In 2024, Boshutai® was successfully included in the VBP by the Henan Seventeen Provinces Alliance for two years. During the Period, order volume of hospitals across participating provinces continued to surge. Revenue of Boshutai® increased by 50.8% from approximately HK$6.1 million to approximately HK$9.2 million. Boshutai® provides a clear demonstration of how disciplined execution across product positioning and supply chain management allows VBP market access to successfully convert into incremental hospital orders and revenue growth. Building on this momentum, the Group will continue to expand its hospital coverage and geographic footprint while strengthening commercialization across multiple sales channels to support sustainable long-term growth.

Bogutai®

The Group's product Bogutai® (teriparatide injection) is effective in treating osteoporosis and bone pain. During the Period, revenue of Bogutai® increased significantly from approximately HK$65.6 million to approximately HK$91.4 million, representing an increase of 39.3%. The strong growth was primarily attributed to the ongoing market development and engagement with this innovative osteoporosis therapy within the medical community and among patients in China. According to an independent China pharmaceutical sales database, as of the first quarter of 2026, Bogutai® ranked second in overall market share and first in the retail channel among teriparatide products in China. Its nationwide sales surpassing those of the originator brand, achieving these market positions within approximately two years of commercial launch.

Bogutai® is mainly distributed in leading 3A hospitals, supported by a dedicated direct sales team focused on key specialties, including orthopedics, endocrinology, and geriatrics. During the Period, the Group organized over 1,000 nationwide academic events to strengthen brand awareness and clinical adoption. Beyond the hospital channel, the Group also expanded its retail and distribution network by delivering more than 60 targeted training sessions for distributors and pharmacy professionals, improving product knowledge and service capabilities. These commercialization initiatives drove continued clinical adoption, with more than 10,000 new patients initiating therapy and nearly 10,000 returning patients during the Period. Supported by an expanding nationwide distribution network, Bogutai® has established a strong commercial presence across China's tier-one to tier-four markets.

肌顏態®

The Group's newly launched medical aesthetic product 肌顏態® is developed with proprietary Skbrella™ FN (Recombinant Human Fibronectin) technology. Fibronectin, a vital extracellular matrix glycoprotein, supports cell migration, adhesion, proliferation, and tissue regeneration. 肌顏態® enhances skin quality and accelerates repair, making it ideal for damaged and acne-prone skin, as well as post-procedure care. Since its official debut in December 2024, the Group has actively promoted the product through marketing campaigns to build brand awareness and drive adoption among aesthetic medical chains and hospitals for post-surgery treatments. With a limited number of product portfolio and the ongoing optimization of its marketing and distribution teams, revenue from 肌顏態® increased from approximately HK$1.3 million to approximately HK$2.2 million, representing a 69.2% YoY growth for the Period.

During the Period, the Group actively participated in professional academic activities in the medical aesthetics field, showcasing the scientific evidence and clinical value of its products through research presentations and professional exchanges. Notably, the Group's joint research project with the Cosmetics Testing Center of the Hospital for Skin Diseases, Southern Medical University on the wound-healing properties of 肌顏態® fibronectin was selected for presentation as an e-Poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting, further strengthening the product's international academic recognition and professional credibility.

During the Period, the Group also officially commenced the commercial launch and market promotion of its high-end series, GeneQueens®, further enriching its portfolio in functional skincare and post-procedure medical aesthetics. The premium line incorporates a proprietary triple-protein complex (Fibronectin, Type III Collagen, and Type XVII Collagen), each formatted at a high concentration of 1,000 ppm to optimize cellular repair and anti-aging performance. This milestone demonstrates concrete progress in accelerating the commercialization of its synthetic biology platform. To accelerate market penetration, the Group is actively promoting medical aesthetics products through diversified marketing initiatives, including digital content marketing, livestream e-commerce, and other emerging online channels, while continuing to strengthen partnerships with medical aesthetics institutions, pharmacy chains, and e-commerce platforms. These initiatives are expected to further enhance brand awareness, expand market reach, and support the long-term growth of the Group's medical aesthetics business.

金因康®

Following market approval from the NMPA in May 2025, 金因康® (Diquafosol Sodium Eye Drops) was launched toward the end of the 2025, providing a novel therapeutic option for dry eye disease. As targeted regions were still operating under the existing VBP contract periods that limited the product's market access, 金因康® made no material revenue contribution during the Period. Leveraging synergies with GeneSoft® and its established online and offline distribution network, the Group will continue to move forward targeted expansion in the non-public sector to build alternative channels and accelerate uptake of 金因康®.

This next-generation product stimulates tear fluid and mucin secretion by activating the P2Y2 receptor, effectively addressing the underlying causes of dry eye syndrome in patients with tear film abnormalities and corneal epithelial defects. 金因康® is among the first BFS-packaged Diquafosol products in the market. The medication specifically targets the mid-to-high-end segment of dry eye patients outside hospital settings, focusing on those who prioritize long-term efficacy and premium product quality.

金因敷®

The Group's newly launched medical device product 金因敷® offers high-purity, non-allergenic formulations with proprietary cooling technology to accelerate wound healing and reduce post-treatment swelling and discomfort. The Group continues to strengthen collaboration with leading hospitals, key opinion leaders, renowned medical aesthetics chains, and distribution partners to accelerate product adoption and drive terminal conversion across major healthcare institutions. In addition, the Group is actively expanding its presence across digital and social media platforms to enhance 金因敷® brand awareness and market reach in the functional medical skincare and post-procedure medical aesthetics segments, laying a solid foundation for future commercial growth.

Revenue contribution from 金因敷® was immaterial during the Period.

FINANCIAL PERFORMANCE REVIEW

Turnover

Sales Developments

For the six month ended 30 June 2026, the Group recorded revenue of approximately HK$273.8 million, representing a decrease of 11.7% YoY.

Biopharmaceutical Products

The Group's biopharmaceutical products include GeneTime®, GeneSoft® and Bogutai®. During the Period, biological pharmaceutical products recorded revenue of approximately HK$204.7 million, representing an increase of 4.9% as compared with the same period last year. Biopharmaceutical products represented 74.8% of total sales for the Period, significantly higher than that 62.9% of the corresponding period last year.

Chemical pharmaceutical products

The Group's high-value generics products include Pinup®, Boshutai® and 金因康®. During the Period, the segment achieved revenue of approximately HK$66.9 million, representing a decrease of 41.9% compared with the same period last year. Chemical pharmaceutical products represented 24.4% of total sales for the Period.

Medical aesthetics products

The Group's medical aesthetics products include 肌顏態® and 金因敷®. During the Period, medical aesthetics products recorded revenue of approximately HK$2.2 million, representing a significant increase of 69.2% as compared with the same period last year. Medical aesthetics products represented 0.8% of total sales for the Period.

Gross Profit and Gross Profit Margin

During the Period, gross profit was approximately HK$222.7 million, representing a decrease of 12.4% as compared with approximately HK$254.1 million for the first half of 2025. Gross profit margin decreased by 0.6 percentage points from 81.9% for the first half of 2025 to 81.3%. The decreases were primarily due to the VBP price reductions and VAT-related net selling price adjustments. Nevertheless, gross margin contraction was significantly cushioned as the Group continued to enhance operating leverage for Bogutai®, shifted its revenue mix toward higher-margin biopharmaceuticals, and maintained strict cost discipline.

Selling and Distribution Expenses

During the Period, selling and distribution expenses were approximately HK$136.2 million, representing an increase of 3.4% from approximately HK$131.7 million for the first half of 2025. The increase was primarily attributable to continued investment in academic promotion, market development and the expansion of out-of-hospital distribution channels.

The Group continued to build the channels and commercial infrastructure needed for differentiated products and broader out-of-hospital access. The percentage of selling expenses relative to revenue increased from 42.4% for the first half of 2025 to 49.8%, reflecting continued commercial effort as the Group's product mix shifted further toward biologic products that remain in the volume ramp-up phase and require greater investment to support market access and volume growth. In particular, the pricing adjustment for GeneTime® preceded the full benefit of broader hospital access and volume ramp-up, while related commercialization activities continued during the Period. Management will remain disciplined on the efficiency and payback of these investments.

Research and Development Expenses

Research and development expenses for the first half of 2026 were approximately HK$19.5 million, representing an increase of 43.2% from approximately HK$13.6 million for the first half of 2025. The increase was primarily attributable to the clinical and regulatory work related to the submission of Bogutai® for the U.S. FDA, as well as the accelerated registration and commercialization of Isavuconazonium sulfate capsules. R&D investment is expected to increase further but still disciplined in the second half of 2026, as several key pipeline programs advance into more intensive stages of development, supporting the Group's long-term innovation strategy and future product launches.

General and Administrative Expenses

For the Period, general and administrative expenses were approximately HK$33.2 million, representing an increase of 10% from approximately HK$30.2 million for the first half of 2025. The expenses accounted for 12.1% of revenue as compared with 9.7% for the same period last year. The increase was primarily driven by higher taxes and surcharges following the implementation of the latest VAT policy for biologics, as well as an increase in administrative expenses incurred by the Dongguan production base.

Other Revenue

Other revenue for the Period was approximately HK$3.5 million, representing a decrease of 21.1% when compared with approximately HK$4.4 million for the same period last year. The decrease was attributable to a decline in the CMO business.

Profit for the Period

Profit for the Period decreased from approximately HK$76.0 million in the first half of 2025 to approximately HK$31.2 million, representing a decline of 59.0%.

Overall, the near-term earnings pressure recorded during the Period marks a strategic transitional phase for the Group. The reduction in gross profit resulted primarily from VBP price reductions and VAT-related net selling price adjustments. To safeguard long-term competitiveness, the Group maintained disciplined capital deployment across pipeline R&D, commercial capabilities, and international market access. Operating leverage is expected to improve progressively as broadened market access translates into volume growth and new products scale across core markets.

Financial Position

Despite the temporary impact of the Group's strategic transformation on its financial performance during the Period, the Group maintained a healthy financial position, supported by a resilient balance sheet and continued improvements across key financial metrics. Operating cash flow remained positive at approximately HK$11.4 million, providing a solid financial foundation to support its long-term growth strategy. Total equity increased to approximately HK$448.7 million as at 30 June 2026, compared with HK$413.2 million as at 31 December 2025, reflecting the continued strengthening of the Group's capital base. Meanwhile, the debt-to-equity ratio decreased from 40.3% at the end of 2025 to 34.9% as of 30 June 2026, while the debt-to-asset ratio decreased from 28.7% to 25.9%, reflecting a stronger capital structure and enhanced financial resilience, positioning the Group to support future R&D investment, commercialization initiatives, and international expansion.

PROSPECTS

Having established a solid strategic foundation in the first half of 2026 through targeted commercial and R&D investments, the Group enters the second half well positioned to accelerate its business transformation. As generic therapies continue to yield ground to higher-margin biopharmaceuticals within the Group's portfolio, this evolving revenue mix is expected to deliver sustained margin expansion over the long term.

The 2026 China Government Work Report recognized biopharmaceuticals as an "emerging pillar industry" for the first time, underscoring strong state support. Simultaneously, industry forecasts from IQVIA project global pharmaceutical spending to reach US$2.4 trillion by 2029 (approximately 5.9% CAGR from 2024), while China's domestic market is set to expand to RMB2,310.2 billion in 2026.

Leveraging its growing innovation capabilities and expanding commercial reach, the Group is uniquely positioned to capture these macro tailwinds and unlock long-term shareholder value.

Expanding Market Reach Through Channel Diversification

Deepening Domestic Omni-Channel Coverage

To support its expanding portfolio within an increasingly regulated pharmaceutical environment, the Group is actively diversifying its commercial channels and deploying targeted marketing strategies for each product to maximize promotional impact.

The Group currently commercializes eight core products and continues to deepen its omni-channel sales network across public hospitals, distributor networks, retail pharmacies, and digital e-commerce platforms. The direct sales force is strengthening academic partnerships across provincial, municipal, and private medical institutions. Concurrently, a network of over 800 authorized distributors continues to drive deeper market penetration into Tier-3 and Tier-4 cities, extending the Group's commercial footprint into lower-tier regional markets.

Beyond traditional hospital channels, the Group has expanded its retail pharmacy coverage to nearly 15,000 locations nationwide, significantly enhancing product accessibility and patient convenience. In parallel, the Group is expanding its digital presence across major e-commerce platforms, including Tmall, JD.com, and Meituan, establishing an integrated ecosystem of official flagship stores, authorized online retailers, and new media channels. Core products such as GeneTime® are now accessible through a seamlessly connected network of online platforms, distributors, retail pharmacy chains, and public hospitals. Moving forward, the Group will continue to build out its online footprint while enhancing online-to-offline operational synergies to establish a more resilient commercial infrastructure.

Tailored Product-Specific Commercialization

The Group implements differentiated commercial strategies tailored to the unique market positioning of each product line. For medical aesthetic and skincare products such as 肌顏態® and 金因敷®, the Group is deepening strategic collaborations with benchmark hospitals, key opinion leaders (KOLs), leading medical aesthetics chains, and specialized agents to drive clinical adoption. In parallel, it is leveraging new media channels to build brand equity within the efficacy-driven medical skincare and post-procedure recovery segments. For GeneQueens®, the Group is exploring innovative commercial models, incorporating targeted content marketing and livestream e-commerce to accelerate consumer reach and conversion.

For 金因康®, which was launched late last year, the Group is advancing compliant academic promotion, brand-building initiatives, professional clinician training, and patient education programs to systematically establish its clinical credibility and standing among healthcare practitioners over time.

Accelerating Global Footprint and Pipeline Synergies

Building on its domestic foundation, the Group is advancing the international commercialization of Bogutai® in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico with Kexing Biopharm. Concurrently, management is also in active discussions with regional distributors across ten additional overseas markets to tailor localized commercial strategies. Bogutai® is expected to generate strong portfolio synergies with Denosumab Injection (in-licensed by Kexing Biopharm), together forming a highly complementary osteoporosis franchise that addresses both the inhibition of bone resorption and the promotion of bone formation.

In parallel, the Group is advancing its U.S. FDA regulatory submission for Bogutai®, targeting approval as early as 2027. Upon regulatory clearance, Bogutai® is anticipated to become the Group's first commercialized therapy in overseas markets, marking a major milestone in its global expansion strategy.

Product Pipeline and Manufacturing Excellence

Beyond its eight commercialized products, the Group continues to actively diversify its pipeline, with several key development projects nearing commercial launch.

Advancing Wound Care Regeneration

The Group's proprietary EGF/FGF compound gel has successfully completed formulation research and preliminary efficacy trials. Unlike conventional liquid-based formulations, this smart, thermosensitive gel provides a sustained-release mechanism that maintains a moist wound-healing environment, accelerates tissue repair, and minimizes scarring. During the Period, the project transitioned into pilot-scale production while advancing non-clinical studies for deep second-degree burns, scalds, and chronic wound healing, with planned clinical indications expanding to include diabetic foot ulcers. Combining dual-growth-factor synergy with advanced thermosensitive delivery technology, the product is well positioned to drive product substitution and market upgrading within this high-demand therapeutic segment.

Selective Portfolio Expansion Leveraging Existing Antifungal Footprint

Building on the Group's established commercial, manufacturing and supply capabilities in the antifungal market, the Group is selectively advancing Isavuconazonium sulfate capsules as a complementary portfolio opportunity. In the antifungal segment, the Group's marketing authorization application for Isavuconazonium sulfate capsules has been formally accepted by the NMPA. Supplementary research requested in the deficiency notice was successfully completed during the first half of 2026, with the final submission package scheduled for delivery to the CDE in the third quarter of 2026. To guarantee high-quality production and long-term supply stability upon commercialization, the Group has retrofitted a dedicated production line and secured strategic supply agreements with premier API suppliers. Regulatory approval is anticipated by the first quarter of 2027, representing a key commercial milestone that will provide patients suffering from invasive fungal infections with a safer and more effective treatment alternative.

Next-Generation BFS Formulation Technology

The Group is leveraging its newly commissioned BFS manufacturing line in Dongguan to accelerate next-generation GeneSoft® formulations, featuring both a 0.5ml single-dose daily disposable and a 3ml multi-dose preservative-free version. NMPA regulatory submissions for both formulations are expected within 2026. BFS technology executes bottle forming, filling, and sealing within a continuous, fully automated aseptic process, ensuring superior product safety alongside optimized cost control. The EGF single-dose eye drops, specifically indicated for corneal epithelial defects, are projected to achieve commercial launch by the end of 2027.

Proprietary Technology Platforms Driving Innovation

The Group continues to harness two proprietary technological engines, the ECO-KSFA® Advanced Synthetic Biology and the Biological Hydrogel Platform, to power its R&D pipeline and commercial transformation.

ECO-KSFA® Advanced Synthetic Biology Platform

Utilizing its proprietary ECO-KSFA® platform, the Group has successfully established a high-yield production process for BMP-2 API, a crucial growth factor in regenerative medicine widely applied in spinal fusion and bone defect reconstruction. During the first half of 2026, the pilot-scale manufacturing process for the BMP-2 drug substance was completed, while development of the sustained-release gel formulation was initiated, establishing a firm foundation for finalizing the product's clinical dosage form. Market approval for this therapy is targeted for 2029. The ECO-KSFA® platform enables kilogram-scale production of complex micro-proteins and peptides with high stability, serving as a core innovation engine for the Group's expansion across pharmaceuticals, medical devices, and medical aesthetics.

Biological Hydrogel Technology Platform

The Group has established an advanced, smart-responsive hydrogel platform utilizing functional polymeric matrices to precisely tune biocompatibility, mechanical strength, and dynamic therapeutic behaviors, including self-healing properties, controlled drug release, and mesenchymal stem cell integration. Designed for targeted, minimally invasive interventions, the platform is currently applied across wound care and bone regeneration. Leveraging the platform's temperature-sensitive gelation capabilities, the EGF/FGF compound gel rapidly transitions into a solid gel matrix at body temperature (37°C), enabling in-situ gelation and prolonged drug delivery. Similarly, the BMP-2 bone repair program utilizes this platform to achieve sustained, localized API delivery. Moving forward, the Group will continue leveraging this platform to drive formulation breakthroughs and upgrade its overall therapeutic delivery systems.

Liquidity and Financial Resources

As at 30 June 2026, the Group's bank deposits, bank balances and cash amounted to approximately HK$158,865,000. The Group had total assets of approximately HK$605,527,000 (as at 31 December 2025: HK$579,803,000), and current assets of approximately HK$349,281,000 (as at 31 December 2025: HK$334,337,000), while current liabilities were at HK$119,220,000 as at 30 June 2026 (as at 31 December 2025: HK$103,545,000). The total current liabilities to total assets ratio is 19.7% as at 30 June 2026 (as at 31 December 2025: 17.20%).

Significant Investments and Future Plans for Material Investments or Capital Assets

During the six months ended 30 June 2026, the Group did not have any significant investments or future plans for material investments or capital assets.

Material Acquisitions and Disposals of Assets, Subsidiaries, Associated Companies and Joint Ventures

Saved as disclosed herein, the Group did not make any material acquisitions and disposals of assets, subsidiaries, associated company and joint ventures during the six months ended 30 June 2026.

Charges on assets

As at 30 June 2026, the Group's land use rights included in right-of-use assets, buildings included in property, plant and equipment and trademarks and certificates included in intangible assets with an aggregate carrying amount of approximately HK$14.4 million (31 December 2025: approximately HK$14.5 million) were pledged to banks as securities for borrowings granted to the Group.

Employment and Remuneration Policy

As at 30 June 2026, the Group employed 568 employees, including 30 employees in the PRC R&D department, 246 employees in the PRC production department, 181 employees in the PRC commercial office, and nine managers and five R&D employees in the Hong Kong headquarters. The Group has adopted a competitive remuneration package for its employees to attract and retain top talent. Promotion and salary increments are assessed based on performance. Share options may also be granted to staff with reference to the individual's performance.

Corporate Governance

The Company has complied with all the applicable code provisions in the Corporate Governance Code set out in Appendix C1 to the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") throughout the six months ended 30 June 2026.

Model Code for Securities Transactions

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") set out in Appendix C3 to the Listing Rules as its own code of conduct regarding directors' dealings in the Company's securities. Specific enquiry has been made of all the directors of the Company and the directors have confirmed that they have complied with the Model Code throughout the six months ended 30 June 2026.

Purchase, Sale or Redemption of the Company's Listed Shares

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed shares.

Events after the Reporting Period

There are no significant subsequent events after the Reporting Period.

Interim Dividend

The Board does not recommend any interim dividend for the six months ended 30 June 2026.

Audit Committee

The audit committee currently comprises the three independent non-executive Directors, namely Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qinshan. The audit committee has reviewed the unaudited consolidated financial statements of the Group of the six months ended 30 June 2026.

Publication of the Consolidated Results and 2026 Interim Report on the Websites of the Stock Exchange and the Company

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.uni-bioscience.com). The interim report for the six months ended 30 June 2026 will be dispatched to the Shareholders and published on the aforementioned websites in due course.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

		Unaudited Six months ended 30 June	
		2026	2025
	Notes	***HK$'000***	*HK$'000*
Revenue	*3*	**273,783**	310,225
Cost of sales		**(51,078)**	(56,141)
Gross profit		**222,705**	254,084
Other revenue		**3,494**	4,426
Other net losses		**1,352**	(3,599)
Selling and distribution costs		**(136,222)**	(131,679)
General and administrative expenses		**(33,224)**	(30,191)
Research and development costs		**(19,528)**	(13,634)
Equity-settled share-based payment expenses		**(376)**	–
Profit from operation		**38,201**	79,407
Finance costs		**(874)**	(758)
Profit before taxation	*4*	**37,327**	78,649
Income tax expense	*6*	**(6,159)**	(2,694)
Profit for the period		**31,168**	75,955
Other comprehensive loss			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation on foreign operations		**22,607**	(2,214)
Other comprehensive loss for the period		**22,607**	(2,214)
Total comprehensive income for the period		**53,775**	73,741
Earnings per share *(HK cents)*			
— Basic and diluted	*7*	**0.52**	1.27

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2026

	Notes	**Unaudited 30 June 2026** ***HK$'000***	Audited 31 December 2025 *HK$'000*
Non-current assets			
Property, plant and equipment	*8*	**173,293**	163,590
Right-of-use assets	*9*	**11,778**	14,485
Intangible assets	*10*	**39,313**	38,196
Loan receivables — non-current portion		**12,588**	12,123
Interest in a jointly controlled entity		**7,287**	7,287
Deposits paid for the acquisition of property, plant and equipment		**6,842**	5,630
Deferred tax assets		**2,674**	2,575
Financial asset at fair value through other comprehensive income		**2,471**	1,580
		256,246	245,466
Current assets			
Inventories		**45,463**	36,999
Trade and other receivables	*11*	**135,911**	108,735
Loan receivables		**9,042**	8,709
Structured short-term bank deposits	*12*	**56,561**	–
Restricted bank balance		**–**	11,072
Bank balances and cash		**102,304**	168,822
		349,281	334,337
Current liabilities			
Trade and other payables	*13*	**35,877**	40,925
Contract liabilities		**25,394**	18,288
Bank borrowings		**48,281**	32,329
Current tax liabilities		**901**	868
Lease liabilities	*9*	**3,394**	5,920
Amount due to a related party		**5,373**	5,215
		119,220	103,545
Net current assets		**230,062**	230,792
Total assets less current liabilities		**486,307**	476,258

	Notes	**Unaudited 30 June 2026** ***HK$'000***	Audited 31 December 2025 *HK$'000*
Non-current liabilities			
Bank borrowings		**30,311**	55,514
Deferred tax liabilities		**1,585**	1,532
Deferred revenue		**2,046**	1,971
Lease liabilities	*9*	**3,657**	3,994
		37,599	63,011
Net assets		**448,708**	413,247
Capital and reserves			
Share capital	*14*	**59,712**	59,712
Reserves		**388,996**	353,535
Total equity		**448,708**	413,247

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

	Unaudited Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
Net cash from operating activities	**11,411**	58,282
Net cash (used in)/from investing activities	**(17,518)**	86,649
Net cash used in financing activities	**(9,153)**	(29,064)
Net (decrease)/increase in cash and cash equivalents	**(15,260)**	115,867
Cash and cash equivalents at the beginning of the period	**168,822**	65,009
Net effect of foreign exchange rate changes	**5,303**	(10,362)
Cash and cash equivalents at the end of the period, represented by bank balances and cash	**158,865**	170,514

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2026

	Attributable to owners of the Company							
	Share capital *HK$'000*	**Share premium** *HK$'000*	**Share-based payment reserve** *HK$'000*	**FVTOCI reserve** *HK$'000*	**Distributable reserve** *(Note a)* *HK$'000*	**Exchange reserve** *(Note b)* *HK$'000*	**Accumulated losses** *HK$'000*	**Total** *HK$'000*
At 1 January 2025 (audited)	59,712	725,692	40,010	–	1,291,798	44,752	(1,836,319)	325,645
Other comprehensive loss for the period	–	–	–	–	–	(2,214)	–	(2,214)
Profit for the period	–	–	–	–	–	–	75,955	75,955
Total comprehensive income for the period	–	–	–	–	–	(2,214)	75,955	73,741
Dividend recognised as distribution	–	(16,541)	–	–	–	–	–	(16,541)
Transfer from share-based payment reserve to accumulated losses	–	–	(5,648)	–	–	–	5,648	–
Recognition of equity-settled share-based payment expenses	–	–	1	–	–	–	–	1
At 30 June 2025 (unaudited)	59,712	709,151	34,363	–	1,291,798	42,538	(1,754,716)	382,846
At 1 January 2026 (audited)	**59,712**	**709,152**	**27,034**	**(68)**	**1,291,798**	**54,624**	**(1,729,005)**	**413,247**
Other comprehensive loss for the period	**–**	**–**	**–**	**–**	**–**	**22,607**	**–**	**22,607**
Profit for the period	**–**	**–**	**–**	**–**	**–**	**–**	**31,168**	**31,168**
Total comprehensive income for the period	**–**	**–**	**–**	**–**	**–**	**22,607**	**31,168**	**53,775**
Dividend recognised as distribution	**–**	**(18,690)**	**–**	**–**	**–**	**–**	**–**	**(18,690)**
Transfer from share-based payment reserve to accumulated losses	**–**	**–**	**(1,833)**	**–**	**–**	**–**	**1,833**	**–**
Recognition of equity-settled share-based payment expenses	**–**	**–**	**376**	**–**	**–**	**–**	**–**	**376**
At 30 June 2026 (unaudited)	**59,712**	**690,462**	**25,577**	**(68)**	**1,291,798**	**77,231**	**(1,696,004)**	**448,708**

Note a: The distributable reserve represents credit arising from Capital Reorganisation effected by the Company during the year ended 31 March 2010. Under the Company Law (revised) of the Cayman Islands, share premium is distributable to shareholders, subject to the condition that the Company cannot declare or pay a dividend, or make a distribution out of share premium if (i) it is, or would after the payment be, unable to pay its liabilities as they become due, or (ii) the realisable value of its assets would thereby be less than the aggregate of its liabilities and its issued share capital accounts.

Note b: Exchange differences relating to the translation of the net assets of the Group's foreign operations from their functional currency to the Group's presentation currency (i.e. Hong Kong dollars) are recognised directly in other comprehensive income and accumulated in the exchange translation reserve. Such exchange differences accumulated in the exchange translation reserve are reclassified to profit or loss on the disposal of the foreign operations.

NOTES TO CONDENSED ACCOUNTS

1. ORGANISATION

The Company is incorporated in the Cayman Islands as an exempted company with limited liability and its shares are listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The address of its registered office is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands. Its principal place of business is located at Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong.

The Group is principally engaged in bioscience related business with focus on the research, development and commercialization of biopharmaceutical products through recombinant DNA and other technologies.

2. BASIS OF PREPARATION AND PRINCIPAL POLICIES

The unaudited condensed consolidated financial statements of the Group have been prepared in accordance with the applicable disclosure requirements of Appendix 16 of the Rules Governing the Listing of Securities on Stock Exchange (the "**Listing Rules**") and Hong Kong Accounting Standard ("**HKAS**") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"). The condensed consolidated financial statements are unaudited but have been reviewed by the Audit Committee of the Company.

The accounting policies adopted and the basis of preparation used in the preparation of the condensed consolidated financial statement of the Group are consistent with those followed in the preparation of the Group's annual financial statements for the twelve months ended 31 December 2025.

In the Period, the Group has applied, for the first time, the following new and amendments to HKFRS Accounting Standards ("**HKFRSs**") and Interpretations issued by the HKICPA that are relevant for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7	Annual Improvements to HKFRS Accounting Standards — Volume 11

The adoption of the above new or revised HKFRSs in the current period did not have any significant impact on the financial position and performance of the Group.

The following amendments to HKAS and HKFRSs, potentially relevant to the Group's condensed consolidated financial statements, have been issued, but are not yet effective and have not been early adopted by the Group.

Amendments to HK Interpretation 5	Presentation of Financial Statements — Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause[1]
HKFRS 18	Presentation and Disclosure in Financial Statements[1]
HKFRS 19	Subsidiaries without Public Accountability: Disclosures[1]
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[2]

[1] Effective for annual periods beginning on or after 1 January 2027.
[2] Effective date to be determined.

The directors of the Company are in the process of analysing the new requirements and assessing the impact of the amendments towards these condensed consolidated financial statements of the Group.

3. SEGMENT INFORMATION

Information reported to the board of directors of the Company, being the chief operating decision maker ("**CODM**"), for the purpose of allocating resources to segments and assessing their performance are organised on the basis of the revenue streams. No operating segments identified by the CODM have been aggregated in arriving at the reportable segments of the Group.

The Group's operating and reportable segments are analysed as follows:

(a)	Chemical pharmaceutical products	—	manufacture and sale of chemical pharmaceutical products
(b)	Biological pharmaceutical products	—	manufacture and sale of biological pharmaceutical products
(c)	Pipeline products	—	industrialisation of pipeline pharmaceutical products

The information of the reportable segment results are as follows:

For the six months ended 30 June 2026 (unaudited)

	Chemical pharmaceutical products *HK$'000*	**Biological pharmaceutical products** *HK$'000*	**Pipeline products** *HK$'000*	**Consolidated** *HK$'000*
Segment revenue				
External sales	**69,055**	**204,728**	**–**	**273,783**
Result				
Segment profit/(loss)	**26,299**	**41,515**	**(19,528)**	**48,286**
Other income				**3,494**
Finance costs				**(874)**
Equity-settled share-based payment expenses				**(376)**
Unallocated administration expenses				**(13,203)**
Profit before taxation				**37,327**

For the six months ended 30 June 2025 (unaudited)

	Chemical pharmaceutical products *HK$'000*	Biological pharmaceutical products *HK$'000*	Pipeline products *HK$'000*	Consolidated *HK$'000*
Segment revenue				
External sales	115,021	195,204	–	310,225
Result				
Segment profit	57,124	28,096	–	85,220
Other income				4,426
Finance costs				(758)
Equity-settled share-based payment expenses				(1)
Unallocated administration expenses				(10,238)
Profit before taxation				78,649

4. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging:

	Unaudited Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
Amortisation of intangible assets	**2,261**	2,291
Cost of inventories recognised as an expenses	**51,078**	56,141
Depreciation of property, plant and equipment	**9,886**	7,221
Depreciation of right-of-use assets	**3,183**	3,201
Less: Depreciation included in research and development costs	**(1,091)**	(1,397)
	11,978	9,025
Research and development costs	**21,450**	13,634
Less: Capitalisation on intangible assets	**(1,922)**	–
	19,528	13,634

5. STAFF COSTS (INCLUDING DIRECTORS' EMOLUMENTS)

	Unaudited Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
Salaries, wages and other benefit	**66,977**	65,419
Retirement benefit scheme contribution	**14,504**	12,246
	81,481	77,665

6. INCOME TAX EXPENSE

The amount of taxation charged to the condensed consolidated statement of comprehensive income represents:

	Unaudited Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
The PRC Enterprise Income Tax ("**EIT**")	**6,159**	2,694

No provision for Hong Kong profits tax has been made since the entities operating in Hong Kong had no assessable profit for both periods.

Under the Law of the People's Republic of China on Enterprise Income Tax (the "**EIT Law**") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% from 1 January 2008 onwards.

Beijing Genetech Pharmaceutical Co., Limited and Shenzhen Watsin Genetech Pharmaceutical Co., Limited, wholly owned subsidiaries of the Company, were approved as "high-new technology enterprise" and were eligible to enjoy a preferential enterprise income tax rate of 15% for the six months ended 30 June 2026 and 2025.

7. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to owners of the Company is based on the following data:

	Unaudited Six months ended 30 June	
	2026	2025
	HK$'000	*HK$'000*
Earnings		
Profit for the period attributable to owners of the Company for the purpose of basic and diluted earnings per share	**31,168**	75,955

	Unaudited Six months ended 30 June	
	2026	2025
	'000	*'000*
Number of shares		
Weighted average number of ordinary shares for the purpose of computation of basic and diluted earnings per share	**5,971,228**	5,971,228

For the six months ended 30 June 2026 and 2025, the computation of diluted earnings per share does not assume the conversion of certain share options as the exercise price of these share options are higher than the average market price of the Company.

8. PROPERTY, PLANT AND EQUIPMENT AND INVESTMENT PROPERTIES

a. Acquisitions and disposals

During the six months ended 30 June 2026, the Group acquired items of plant and machinery with a cost of HK$17,099,000 (six months ended 30 June 2025: HK$21,169,000). Items of plant and machinery with a net book value of HK$8,000 were disposed of during the six months ended 30 June 2026 (six months ended 30 June 2025: HK$32,300), resulting in a gain on disposal of HK$3,000 (six months ended 30 June 2025: a loss on disposal of HK$32,300).

b. Impairment losses

During the six months ended 30 June 2026 and 2025, no impairment loss of Property, Plant and Equipment and Investment properties were recognised by the Group.

9. RIGHT-OF-USE-ASSETS AND LEASE LIABILITIES

Right-of-use assets

The analysis of the net book value of right-of-use assets by class of underlying asset is as follows:

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Land use rights, carried at depreciated cost	**6,374**	6,280
Leased properties, carried at depreciated cost	**5,404**	8,205
	11,778	14,485

The right-of-use assets represent the Group's rights to use underlying leased premises under operating lease arrangements over the lease terms, which are stated at cost less accumulated depreciation and accumulated impairment losses, and adjusted for any remeasurement of the lease liabilities.

Lease Liabilities

The carrying amount of lease liabilities are as follows:

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Maturity analysis		
Less than one year	**3,394**	5,920
Over one year and more	**3,657**	3,994
Total lease liabilities	**7,051**	9,914
Analysed as:		
Current portion	**3,394**	5,920
Non-current portion	**3,657**	3,994
	7,051	9,914

10. INTANGIBLE ASSETS

Carrying amount

	Trademarks and certificates *(Note a)* *HK$'000*	**Technical know-how** *(Note b)* *HK$'000*	**Capitalised development costs** *(Note c)* *HK$'000*	**Total** *HK$'000*
At 30 June 2026 (unaudited)	**–**	**1,783**	**37,530**	**39,313**
At 31 December 2025 (audited)	–	1,909	36,287	38,196

All intangible assets are amortised on a straight-line basis over the following periods:

Trademarks and certificates	10 to 15 years
Technology know-how	10 years
Capitalised development costs	10 years

Notes:

(a) Trademarks and certificates represent costs in obtaining trademarks and registration certificates for pharmaceutical products.

(b) Technical know-how mainly represents techniques and formulas acquired separately for the development of products and production technology.

(c) Capitalised development costs mainly represent costs generated internally for the development of products and product technology.

(d) Except for the capitalised development costs of drugs under development, the respective intangible assets (including the capitalised development costs of drugs already completed development) have finite lives and are subsequently amortised over the useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Capitalised development costs of drugs under development are not amortised as the development of products and technology is in the registration or after the approval of phase III clinical trial process and are assessed for impairment annually.

(e) The directors of the Company conducted an impairment review of the Group's intangible assets annually. During the six months ended 30 June 2026 and 2025, no impairment loss on technical know-how and capitalised development costs were recognised to profit or loss.

11. TRADE AND OTHER RECEIVABLES

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Trade receivables	**108,459**	77,232
Less: Loss allowance	**(9,152)**	(8,814)
	99,307	68,418
Bill receivables	**14,014**	22,007
Deposits, prepayments and other receivables	**23,148**	18,861
Less: Loss allowance	**(558)**	(551)
	22,590	18,310
	135,911	108,735

Note: As at 30 June 2026 and 31 December 2025, trade receivables from contracts with customers amounted to HK$99,307,000 and HK$68,418,000 respectively.

The following is an ageing analysis of trade receivables based on the invoice dates, as at the end of the reporting period:

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
0–90 days	**82,248**	64,872
91–120 days	**20,167**	6,091
121–180 days	**3,487**	2,673
181–360 days	**1,711**	845
Over 360 days	**846**	2,751
	108,459	77,232
Less: Loss allowance	**(9,152)**	(8,814)
	99,307	68,418

12. STRUCTURED SHORT-TERM BANK DEPOSITS

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Financial assets measured at FVTPL:		
At the beginning of the period/year	**–**	104,884
Addition	**267,534**	–
Changes in fair value	**–**	351
Derecognition	**(210,973)**	(105,235)
	56,561	–
Analysed for reporting purpose as:		
Current assets	**56,561**	–

Note:

During the six months ended 30 June 2026, the Group entered into structured short-term bank deposits agreements ("**Deposits Agreements**") with a bank in the PRC. The bank guaranteed 100% of the invested principal amount and floating interest rates of 1.30% to 2.00% p.a. with maturity periods ranging from 7 days to 92 days, the floating interest rates apply on such deposits are linked to the GoldInpm Index as specified in the Deposits Agreements.

13. TRADE AND OTHER PAYABLES

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Trade payables	**18,630**	21,166
Other payables	**6,950**	7,725
Accruals	**10,297**	12,034
	35,877	40,925

The ageing analysis of trade payables at the end of the reporting period based on transaction date is as follows:

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
0–30 days	**6,201**	9,125
31–60 days	**1,429**	1,141
61–90 days	**406**	394
Over 90 days	**10,594**	10,506
	18,630	21,166

The average credit period on purchases of goods is 120 days (31 December 2025: 120 days). The Group has in place financial risk management policies to ensure that all payables are settled within the credit time frame.

14. SHARE CAPITAL

Ordinary share of HK$0.01 each

	Number of shares	Amount *HK$'000*
Authorised:		
At 31 December 2025 and 30 June 2026	500,000,000,000	5,000,000
Issued and fully paid:		
At 31 December 2025 and 30 June 2026	5,971,228,147	59,712

15. SHARE OPTIONS

On 26 September 2016, a New Share Option Scheme was adopted by the Company ("**2016 Scheme**") and replaced the share option scheme approved on 22 September 2006.

Under the 2016 Scheme, which is valid for a period of ten years, the board of directors of the Company may, at its discretion grant options to subscribe for shares in the Company to eligible participants ("**Eligible Participants**") who contribute to the development and growth of the Group. Eligible Participants include (i) any employee (whether full-time or part-time including any executive director but excluding any non- executive director) of the Company, any of its subsidiaries or any entity ("**Invested Entity**") in which the Group holds an equity interest; (ii) any non-executive director (including independent non-executive director) of the Company, any of its subsidiaries or any Invested Entity; (iii) any supplier of goods or services to any member of the Group or any Invested Entity; (iv) any customer of any member of the Group or any Invested Entity; (v) any person or entity that provides research, development or other technological support to any member of the Group or any Invested Entity; (vi) any adviser (professional or otherwise) or consultant to any area of business or business development of the Group or any Invested Entity; and (vii) any other group or classes of participants who have contributed or may contribute by way of joint venture, business alliance or other business arrangement to the development and growth of the Group, and, for the purposes of the New Share Option Scheme, the options may be granted to any company wholly owned by one or more persons belonging to any of the above classes of participants.

At 30 June 2026, the number of shares in respect of which options had been granted and remained outstanding under the share option scheme was 712,195,000 (At 31 December 2025: 432,895,000), representing 11.93% (At 31 December 2025: 7.25%) of the ordinary shares in issue at that date.

On 26 May 2026, the Shareholders approved the termination of the existing share option scheme, the adoption of the new share option scheme and the service provider sublimit at the EGM.

Details of the share option movements during the six months ended 30 June 2026 and 2025 are as follow:

Share options grant date	Outstanding at 1.1.2026 *'000*	Granted during the period *'000*	Exercised during the period *'000*	Lapsed during the period *'000*	Cancelled during the period *'000*	Outstanding at 30.06.2026 *'000*
27 January 2016 Employees	**20,700**	**–**	**–**	**20,700**	**–**	**–**
27 January 2016 Others	**1,300**	**–**	**–**	**1,300**	**–**	**–**
7 October 2016 Directors	**10,880**	**–**	**–**	**–**	**–**	**10,880**
3 April 2017 Employees	**34,950**	**–**	**–**	**–**	**–**	**34,950**
3 April 2017 Others	**2,010**	**–**	**–**	**–**	**–**	**2,010**
16 November 2017 Directors	**16,073**	**–**	**–**	**–**	**–**	**16,073**
9 April 2018 Senior Management	**11,990**	**–**	**–**	**–**	**–**	**11,990**
9 April 2018 Employees	**20,224**	**–**	**–**	**–**	**–**	**20,224**
5 July 2018 Others	**3,000**	**–**	**–**	**–**	**–**	**3,000**
9 April 2019 Directors	**66,179**	**–**	**–**	**–**	**–**	**66,179**
9 April 2019 Employees	**62,449**	**–**	**–**	**–**	**–**	**62,449**
9 April 2019 Others	**3,300**	**–**	**–**	**–**	**–**	**3,300**
2 April 2020 Employees	**35,780**	**–**	**–**	**–**	**–**	**35,780**
2 April 2020 Others	**35,000**	**–**	**–**	**–**	**–**	**35,000**
31 August 2020 Executive Directors	**33,380**	**–**	**–**	**–**	**–**	**33,380**
31 August 2020 Non-Executive Directors	**25,680**	**–**	**–**	**–**	**–**	**25,680**
1 November 2024 Non-Executive Directors	**50,000**	**–**	**–**	**–**	**–**	**50,000**
24 June 2026 Directors	**–**	**300,000**	**–**	**–**	**–**	**300,000**
	432,895	**300,000**	**–**	**22,000**	**–**	**710,895**
Exercisable at the end of the period						**377,395**
Weighted average exercise price	**HK$0.15**	**–**	**–**	**–**	**–**	**HK$0.15**

Share options grant date	Outstanding at 1.1.2025 *'000*	Granted during the period *'000*	Exercised during the period *'000*	Lapsed during the period *'000*	Cancelled during the period *'000*	Outstanding at 30.06.2025 *'000*
23 January 2015 Employees	10,880	–	–	(10,880)	–	–
23 January 2015 Others	33,100	–	–	(33,100)	–	–
10 July 2015 Directors	7,260	–	–	–	–	7,260
17 August 2015 Others	120,000	–	–	–	–	120,000
27 January 2016 Employees	20,700	–	–	–	–	20,700
27 January 2016 Others	1,300	–	–	–	–	1,300
7 October 2016 Directors	10,880	–	–	–	–	10,880
3 April 2017 Employees	34,950	–	–	–	–	34,950
3 April 2017 Others	2,010	–	–	–	–	2,010
16 November 2017 Directors	16,073	–	–	–	–	16,073
9 April 2018 Senior Management	11,990	–	–	–	–	11,990
9 April 2018 Employees	20,224	–	–	–	–	20,224
5 July 2018 Others	3,000	–	–	–	–	3,000
9 April 2019 Directors	66,179	–	–	–	–	66,179
9 April 2019 Employees	62,449	–	–	–	–	62,449
9 April 2019 Others	3,300	–	–	–	–	3,300
2 April 2020 Employees	35,780	–	–	–	–	35,780
2 April 2020 Others	35,000	–	–	–	–	35,000
31 August 2020 Executive Directors	33,380	–	–	–	–	33,380
31 August 2020 Non-Executive Directors	25,680	–	–	–	–	25,680
1 November 2024 Non-executive Directors	50,000	–	–	–	–	50,000
	604,135	–	–	(43,980)	–	560,155
Exercisable at the end of the period						526,655
Weighted average exercise price	HK$0.17	–	–	–	–	HK$0.17

16. CAPITAL COMMITMENT

	Unaudited 30 June 2026	Audited 31 December 2025
	HK$'000	*HK$'000*
Capital expenditure contracted for but not provided in the consolidated financial statements in respect of		
— purchase of property, plant and equipment	**10,963**	14,985
— purchase of intangible asset	**8,900**	10,000
— research and development activities	**2,213**	6,848
	22,076	31,833

17. INTERIM DIVIDEND

The directors of the Company do not recommend the payment of an interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

18. CAPITAL MANAGEMENT

The Group's objectives when managing capital are:

To safeguard the Group's ability to continue as a going concern, so that it continues to provide returns for shareholders and benefits for other stakeholders;

To support the Group's stability and growth; and

To provide capital for the purpose of strengthening the Group's risk management capability.

The Group actively and regularly reviews and manages its capital structure to ensure optimal capital structure and shareholder returns, taking into consideration the future capital requirements of the Group and capital efficiency, prevailing and projected profitability, projected operating cash flows, projected capital expenditures and projected strategic investment opportunities.

By Order of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 26 August 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.